This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on ISI (9)  • Contact me when this article is cited  Related Content  • Related letters  • Related article  • Similar articles in JAMA  Topic Collections  • Evidence-Based Medicine  • Leukemias/ Lymphomas  • Statistics and Research Methods  • Immunologic Disorders  • Randomized Controlled Trial  • Rheumatoid Arthritis  • Adverse Effects  • Alert me on articles by topic

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: Dr Bongartz and colleagues¹ reported the results of a meta-analysis of randomized clinical trials of the TNF-blocking monoclonal antibodies infliximab and adalimumab, finding an increased risk of serious infections and malignancies associated with their use. However, previous meta-analyses of randomized clinical trials of infliximab and adalimumab were conducted at the request of the US Food and Drug Administration (FDA), leading to revised product labeling for infliximab in September 2005 and for adalimumab in October 2005.

The FDA-requested analyses differ in several important respects from that of Bongartz et al. First, the FDA requested that the analyses be adjusted for duration of exposure, since a greater dropout rate in the control arms than in the TNF-blocker arm (due to lack of efficacy) hinders subsequent ascertainment of events in the control arm. Second, the FDA requested meta-analyses for all 3 approved TNF-blockers, including etanercept, not just the TNF-blocking monoclonal . . . [Full Text of this Article]

Sarah K. Okada, MD; Jeffrey N. Siegel, MD
Jeffrey.Siegel@fda.hhs.gov
Division of Anesthesia, Analgesia, and Rheumatology Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research
US Food and Drug Administration
Silver Spring, Md

RELATED LETTERS

Risk of Serious Infections and Malignancies With Anti-TNF Antibody Therapy in Rheumatoid Arthritis
Karen H. Costenbader, Roberta Glass, Jing Cui, and Nancy Shadick
JAMA. 2006;296(18):2201.
EXTRACT | FULL TEXT  

Risk of Serious Infections and Malignancies With Anti-TNF Antibody Therapy in Rheumatoid Arthritis
Peter E. Callegari, Thomas F. Schaible, and Jerome A. Boscia
JAMA. 2006;296(18):2202.
EXTRACT | FULL TEXT  

Risk of Serious Infections and Malignancies With Anti-TNF Antibody Therapy in Rheumatoid Arthritis
David Hochman and Bruce Wolff
JAMA. 2006;296(18):2203.
EXTRACT | FULL TEXT  

Risk of Serious Infections and Malignancies With Anti-TNF Antibody Therapy in Rheumatoid Arthritis—Reply
Tim Bongartz, Eric L. Matteson, Victor M. Montori, Alex J. Sutton, Michael Sweeting, and Iain Buchan
JAMA. 2006;296(18):2203-2204.
EXTRACT | FULL TEXT  

RELATED ARTICLE

Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and Malignancies: Systematic Review and Meta-analysis of Rare Harmful Effects in Randomized Controlled Trials
Tim Bongartz, Alex J. Sutton, Michael J. Sweeting, Iain Buchan, Eric L. Matteson, and Victor Montori
JAMA. 2006;295(19):2275-2285.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007
Furst et al.
Ann Rheum Dis 2007;66:iii2-iii22.
FULL TEXT